$322 Million is the total value of RTW INVESTMENTS, LP's 44 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 88.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALNY | Buy | Alnylam Pharmaceuticals Inc | $42,885,000 | -13.0% | 533,660 | +29.8% | 13.32% | -7.1% |
| INCY | Buy | Incyte Corp | $33,453,000 | +64.6% | 303,212 | +55.5% | 10.39% | +75.7% |
| LJPC | Buy | La Jolla Pharmaceutical Co | $30,022,000 | +331.8% | 1,080,331 | +280.8% | 9.33% | +360.9% |
| BCRX | Sell | BioCryst Pharmaceuticals Inc | $25,402,000 | -24.8% | 2,228,206 | -1.5% | 7.89% | -19.7% |
| KITE | Sell | Kite Pharma Inc | $20,907,000 | -14.3% | 375,476 | -6.1% | 6.50% | -8.5% |
| ACHN | Buy | Achillion Pharmaceuticals Inc | $17,896,000 | -19.7% | 2,589,818 | +3.0% | 5.56% | -14.3% |
| MRTX | New | Mirati Therapeutics Inc | $16,593,000 | – | 482,069 | +100.0% | 5.16% | – |
| DRNA | Buy | Dicerna Pharmaceuticals Inc | $16,463,000 | -7.8% | 2,005,238 | +56.7% | 5.12% | -1.6% |
| BLUE | Buy | bluebird bio Inc | $12,969,000 | -26.6% | 151,594 | +44.4% | 4.03% | -21.7% |
| New | Arrowhead Research Corp | $12,080,000 | – | 2,097,185 | +100.0% | 3.75% | – | |
| FPRX | Buy | Five Prime Therapeutics Inc | $10,988,000 | -21.1% | 713,954 | +27.4% | 3.41% | -15.7% |
| AGEN | Buy | Agenus Inc | $9,587,000 | -45.9% | 2,084,142 | +1.5% | 2.98% | -42.2% |
| New | Atara Biotherapeutics Inc. | $8,269,000 | – | 262,995 | +100.0% | 2.57% | – | |
| CLDX | Buy | Celldex Therapeutics Inc | $7,575,000 | -36.3% | 718,729 | +52.4% | 2.35% | -32.0% |
| SSRG | Buy | Symmetry Surgical Inc | $7,186,000 | +17.6% | 807,442 | +15.2% | 2.23% | +25.5% |
| BMY | Buy | Bristol-Myers Squibb Co | $6,064,000 | -6.5% | 102,425 | +5.1% | 1.88% | -0.2% |
| CORI | Buy | Corium International Inc | $5,378,000 | +10.7% | 575,212 | +62.0% | 1.67% | +18.1% |
| OMER | New | Omeros Corp | $5,370,000 | – | 490,000 | +100.0% | 1.67% | – |
| RGNX | New | Regenxbio Inc | $4,505,000 | – | 204,494 | +100.0% | 1.40% | – |
| GBT | New | Global Blood Therapeutics Inc | $3,896,000 | – | 92,399 | +100.0% | 1.21% | – |
| BMY | New | BMY 01/15/2016 CALL 60call | $2,588,000 | – | 7,500 | +100.0% | 0.80% | – |
| LPCN | Buy | Lipocine Inc | $2,514,000 | +40.0% | 212,497 | +1.5% | 0.78% | +49.3% |
| IVTY | Buy | Invuity Inc | $2,454,000 | +5.3% | 175,000 | +6.1% | 0.76% | +12.4% |
| DYAX | Sell | Dyax Corp | $2,202,000 | -85.1% | 115,358 | -79.4% | 0.68% | -84.1% |
| LENS | Presbia Plc | $1,918,000 | -33.3% | 350,000 | 0.0% | 0.60% | -28.8% | |
| CBIO | New | Catalyst Biosciences Inc | $1,775,000 | – | 380,806 | +100.0% | 0.55% | – |
| RPRX | Buy | Repros Therapeutics Inc | $1,730,000 | +5.5% | 232,830 | +1.5% | 0.54% | +12.8% |
| VBIV | New | Vbi Vaccines Inc | $1,716,000 | – | 650,000 | +100.0% | 0.53% | – |
| OSUR | New | OraSure Technologies Inc | $1,434,000 | – | 322,996 | +100.0% | 0.45% | – |
| CYTR | Buy | CytRx Corp | $1,075,000 | -35.3% | 453,465 | +1.5% | 0.33% | -31.0% |
| NLNK | Sell | NewLink Genetics Corp | $1,014,000 | -77.1% | 28,291 | -71.7% | 0.32% | -75.6% |
| MASI | New | Masimo Corp | $999,000 | – | 25,900 | +100.0% | 0.31% | – |
| MDRX | New | Allscripts Healthcare Solutions Inc | $595,000 | – | 48,000 | +100.0% | 0.18% | – |
| BCRX | New | BCRX 12/18/2015 CALL 12call | $431,000 | – | 2,000 | +100.0% | 0.13% | – |
| NVLS | Nivalis Therapeutics Inc | $389,000 | -14.5% | 30,000 | 0.0% | 0.12% | -8.3% | |
| BPMX | Biopharmx Corp | $382,000 | -59.7% | 370,636 | 0.0% | 0.12% | -56.9% | |
| NTRA | New | Natera Inc | $344,000 | – | 31,693 | +100.0% | 0.11% | – |
| GHDX | New | Genomic Health Inc | $317,000 | – | 15,000 | +100.0% | 0.10% | – |
| ELGX | New | Endologix Inc | $184,000 | – | 15,000 | +100.0% | 0.06% | – |
| VCYT | New | Veracyte Inc | $117,000 | – | 25,000 | +100.0% | 0.04% | – |
| ADAP | Sell | Adaptimmune Therapeutics-adrsponds adr | $84,000 | -77.1% | 7,028 | -64.9% | 0.03% | -75.7% |
| VIVO | New | VIVO 01/15/2016 CALL 20call | $50,000 | – | 1,252 | +100.0% | 0.02% | – |
| USO | New | USO 01/15/2016 CALL 25call | $42,000 | – | 13,850 | +100.0% | 0.01% | – |
| New | Berkshire Hathaway Inccl b new | $7,000 | – | 50 | +100.0% | 0.00% | – | |
| BRKB | Exit | Berkshire Hathaway Inc | $0 | – | -50 | -100.0% | -0.00% | – |
| FBIO | Exit | Fortress Biotech Inc | $0 | – | -11,917 | -100.0% | -0.01% | – |
| Exit | Valeant Pharmaceuticals Intl VRX 10/16/2015 CALL 260call | $0 | – | -150 | -100.0% | -0.02% | – | |
| ZGNX | Exit | Zogenix Inc | $0 | – | -114,128 | -100.0% | -0.06% | – |
| Exit | Meridian Bioscience Inc. VIVO 10/16/2015 CALL 20call | $0 | – | -3,756 | -100.0% | -0.08% | – | |
| USO | Exit | United States Oil ETF | $0 | – | -165,000 | -100.0% | -0.96% | – |
| TLT | Exit | iShares 20+ Year Treasury Bond ETF | $0 | – | -33,000 | -100.0% | -1.13% | – |
| Exit | Bristol Myers Squibb Co 01/15/2016 CALL 60call | $0 | – | -7,500 | -100.0% | -1.78% | – | |
| TRGT | Exit | Targacept Inc | $0 | – | -2,665,643 | -100.0% | -2.16% | – |
| ARWR | Exit | Arrowhead Research Corp | $0 | – | -2,560,000 | -100.0% | -5.33% | – |
| Exit | La Jolla Pharmaceutical Company Cmn Di | $0 | – | -780,547 | -100.0% | -5.57% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-05-24
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.